Home
Live Updates
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update : comparemela.com
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
Reported €30.2 million in cash and cash equivalents as of March 31, 2023PARIS and CAMBRIDGE, Mass., May 17, 2023 -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering... | May 17, 2023
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Paris ,
France General ,
France ,
Texas ,
United States ,
Wattignies ,
Nord Pas De Calais ,
Germany ,
New York ,
Massachusetts ,
Spain ,
French ,
,
University Of Texas Md Anderson Cancer Center ,
Nasdaq ,
Euronext ,
Twitter ,
European Investment Bank ,
Linkedin ,
Meeting Of The Company ,
Laurent Levy ,
Chief Medical Officer ,
Expected Upcoming ,
Medical Officer ,
Advanced Head ,
Priority Registration Pathway ,
Locally Advanced Head ,
Neck Squamous Cell Carcinoma ,
Local Control ,
Single Agent Activated ,
Metastatic Head ,
Priority Pathway ,
Priming Immune Response Followed ,
World Class Partner ,
Validate Tumor Agnostic ,
Combination Agnostic Therapeutic Profile ,
Cash Equivalents ,
Annual General Meeting ,
Euronext Paris ,
Nasdaq Global Select Market ,
New York City ,
Nanobiotix Stock Exchange ,
News ,
Information ,
Press Release ,
Eported ,
Billion ,
N ,
Cash ,
End ,
Equivalents ,
Us ,
F ,
Arch ,
023paris ,
Bay ,
023 ,
Nanobiotix ,
Stage ,
Biotechnology ,
Ompany Nano Fr0011341205 ,
comparemela.com © 2020. All Rights Reserved.